First AD

Second AD

Novel Therapeutics in Development for CSU

Video content above is prompted by the following:

Can you describe what you see as the current and future role of advanced treatments such as biologics and BTK inhibitors in CSU management?

What gap currently exists in transitioning from antihistamine cycling to a biologic?

Evolving Perspectives and Treatment Strategies in Chronic Spontaneous Urticaria 

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Steroids are often employed in the management of chronic spontaneous urticaria (CSU) to provide rapid relief from severe symptoms. However, their use is typically limited to short-term interventions due to potential adverse effects associated with long-term systemic steroid use. Practitioners should exercise caution, considering the risk of side effects such as osteoporosis, hypertension, and glucose intolerance. It is crucial to balance the benefits of symptom control with the potential for harm, and to explore alternative therapies for long-term management to minimize reliance on systemic steroids.

Panelists discuss how the integration of advanced treatments such as biologics and Bruton tyrosine kinase (BTK) inhibitors can bridge the gap in managing chronic spontaneous urticaria (CSU) for patients unresponsive to antihistamines.

Bringing CSU Back Under The House of Dermatology

Understanding the Chronicity of CSU